Compare GDHG & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDHG | CVKD |
|---|---|---|
| Founded | 2008 | 2022 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 20.7M |
| IPO Year | 2023 | 2023 |
| Metric | GDHG | CVKD |
|---|---|---|
| Price | $2.69 | $7.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 12.1K | ★ 78.1K |
| Earning Date | 07-11-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,666,899.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.40 | $6.76 |
| 52 Week High | $1,968.41 | $22.90 |
| Indicator | GDHG | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 27.81 | 35.40 |
| Support Level | $2.52 | $6.76 |
| Resistance Level | $3.08 | $12.50 |
| Average True Range (ATR) | 0.39 | 1.07 |
| MACD | -0.03 | -0.24 |
| Stochastic Oscillator | 8.52 | 9.41 |
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.